Introduction
Plasma cell myeloma (PCM) is a haematological malignancy characteri ed by accumulation of clonal malignant plasma cells predominantly within the bone marrow (BM) 1 . The role of proliferation, apoptosis, and angiogenesis-related defects has been considered in the pathogenesis of PCM, while a very heterogeneous prognosis of the disease necessitates assessment of prognostic factors and prognostic stratification for implementation of individuali ed targeted therapy 2 . Progressive increase in the bone marrow microvessel density (M D) is a prominent feature of active PCM, while along with increased angiogenic cytokine expression it has been associated with pathogenesis and progression of PCM as well as survival 1 . Although the exact mechanisms regulating the progressive increase in angiogenesis in PCM remain unclear, expression of proangiogenic molecules such as vascular endothelial growth factor ( EGF) with stimulatory e ects on endothelial cell growth and microvascular permeability is considered to drive tumor related angiogenesis and to in uence critical steps of myeloma pathogenesis and progression 3-8 . The hypoxic microenvironment of bone marrow in PCM induces tumor angiogenesis via expression of hypoxia-inducible transcription factor 1 alpha ( F-1 ) that leads to the upregulation of proangiogenetic EGF and to subse uent increase in the bone marrow angiogenesis and thus growth of myeloma cells 9-11 . n hypoxic conditions, F-1 can also interact with its transcriptional coactivators including p300 and cyclic AMP response element-binding (C EB) protein (CBP), highly homologous proteins that are re uired for the optimal function of F-1 transcription machinery and subse uent angiogenesis. They have also been shown to play a role in tumorigenesis 11-12 . To our knowledge no data exist investigating the potential prognostic role of p300 expression in patients with PCM. The present study was designed to evaluate angiogenesis-related immunohistochemical parameters including EGF, M D, and p300 in newly-diagnosed PCM patients in terms of their potential association with clinicopathological and laboratory parameters, histomorphologic prognostic factors, and survival.
Material and Method

Study population
A er obtaining ethics committee approval from Ga i niversity School of Medicine and informed consents, 76 consecutive patients with newly-diagnosed PCM between 2001 and 2010 at Ga i niversity School of Medicine were enrolled. 45 of 76 patients mean (SD) age: 58.6(10.8) years 62.2 were males who had available clinical data and para n-embedded tissues for the immunohistochemical analysis of p300 expression, EGF expression, and M D were included in this study.
Assessments
Data on patient demographics, disease characteristics including clinical stage ( -), risk group (low, moderate, high), and laboratory findings serum M protein ( gG, gA, gD, kappa, lambda, non-secretory), light chain (kappa, lambda), hemoglobin (g/d ), BC (e3/ ), platelet count (e3/ ), serum calcium (mg/d ), se-
, erythrocyte sedimentation rate (ES mm/h), proteinuria (g/24 h) and presence of urinary M protein were retrieved from medical records at initial diagnosis. The clinical stage of the patients was classified according to the Durie and Salmon s criteria 13 . isk groups were examined according to the classification of Bataille et al. depending on serum C P and beta-2 microglobulin ( 2M) levels 14 . Formalin-fixed para n-embedded bone marrow specimens were re-evaluated in terms of histomorphologic factors and immunohistochemical analysis for p300 expression, EGF expression, and M D. Demographic, clinical and laboratory parameters, as well as overall survival were evaluated with respect to level of p300 expression, EGF expression, and M D.
Histopathological examination
ematoxylin and eosin-and CD138-stained sections of bone marrow prepared at the time of initial diagnosis were obtained from the archive of the Department of Pathology and re-evaluated for identification of plasmacytic di erentiation and immunohistological assessment of plasma cell morphology, the percentage of plasma cell infiltration ( 20 20- 
Immunohistochemical analysis
For immunohistochemical staining, 3-to 4-m thick tissue sections were cut on slides from formalin-fixed, para n-embedded bone marrow biopsies of the patients. The slides were deparaffini ed for 2 hours in a 60 C oven, and stained for Factor related antigen (von illebrand factor Ab-2 1:100 dilution, clone F8/86, mouse monoclonal, Neomarkers, SA), EGF (1:50 dilution, clone G1, mouse monoclonal, gG1 Kappa, Thermo Scientific, SA), p300 (1:50 dilution, clone Sc-585, rabbit polyclonal, gG, Santa Cru , SA), and CD138 antibody (1:40 dilution, rabbit polyclonal, gG, ThermoFisher Scientific, ockford, SA) in an automatised stainer (Ventana automated immunostainer Discovery T, entana Medical Systems nc., Tucson, SA) by using established protocols. mmunostaining was completed with the diaminoben idine (DAB) detection kit ( entana), which uses a streptavidin-biotin techni ue and hematoxylin as a counterstain. Sections of breast invasive ductal carcinoma for p300, angiosarcoma for EGF, placenta for Factor , and tonsil for CD138 were used as positive controls. For negative controls, the primary antibodies were omitted. Cytoplasmic staining was considered as positive for Factor and EGF nuclear staining was considered as positive for p300 and membranous staining was considered as positive for CD138. Each slide was evaluated under a light microscope (B 53, lympus, Tokyo, apan) by two referral pathologists (SS, NA) blinded to the cases. The measurement of M D was determined immunohistochemically with Factor . Any positively stained endothelial cell or endothelial cell cluster that was clearly separated from adjacent microvessels was considered as a single, countable microvessel. Slides stained with antibodies to Factor antigen/ von illebrand complex were first scanned with light microscopy under low power ( 10 objective) to identify areas with the greatest number of microvessels (hot spots). The microvessels (capillaries and small venules) at hot spots were counted at one high power field ( PF) (x40 objective with eyepiece diameter of 0.65 mm) of the microscope. Then, M D was counted as the average number of vessels in the three hot spots. Microvessels were identified as endothelial cells either single or clustered in nests or tubes, clearly separated from one another, with or without lumen not exceeding 10 micrometers in transverse diameter. arger vessels and vessels in the periosteum were excluded. M D was categori ed into two groups based on the number of microvessels including low ( 20 microvessels/ PF) and high ( 20 
Statistical analysis
Statistical analysis was conducted using SPSS so ware, version 15.0. Chi-s uare ( 2 ) and Fisher s exact tests for the comparison of categorical data, while numerical data were analy ed using Student t-test and AN A. Spearman correlation analysis was used to analy e correlation between immunohistochemical parameters. Survival analysis was made via Kaplan-Meier analysis and comparisons were made via og-ank test. Data were expressed as mean (standard deviation, SD) , minimummaximum, and percent ( ) where appropriate. p 0.05 was considered statistically significant.
Results
Demographic and clinical characteristics
Most of the patients had clinical stage -disease (82.2 ) with intermediate-grade cytology (62.2 ), di use type of infiltration pattern (44.4 ), and plasma cell infiltration of 50 (68.9 ) and were categori ed into the moderate risk group (50.0 ) ( Table 1) .
verall, mean (SD) M D score was 23.7(13.2, ranged 3 to 54) microvessels/ PF, while M D score was 20 microvessels/ PF in 19(42.2 ) patients, and 20 microvessels/ PF in 26(57.8 ) patients (Fig 1) . Mean (SD) extent of EGF expression was 64.2 (29.2, ranged 5 to 100) , while EGF expression was 10 , 10-49 and 50 in 3(6.7 ), 11(24.4 ) and 31(68.9 ) patients, respectively (Fig  2) . Mean (SD) p300 expression was 38.7 (31.8, ranged 0 to 90) while p300 expression was 30 in 17(37.8 ) and 30 in 28(62.2 ) patients (Fig 3) . No significant di erence was noted in patient demographics, clinical stage, histomorphologic prognostic factors, or risk group in terms of p300 expression (Table 1) .
igher ( 50 ) Fig 4) . No significant di erence was noted in percentage of survivors and median duration of S with respect to p300, EGF, and M D (Table 1, Fig 4) .
Laboratory parameters
igher ( 20 microvessels) than lower ( 20 microvessels) M D scores (78.3 vs. 21.7 , p 0.015) were more likely seen in patients with C P levels of 6 mg/ ( Table 2) . None of the laboratory parameters showed a significant change with respect to p300 or EGF. Apart from C P, no significant change was observed in laboratory parameters also with respect to M D (Table 2) . Correlation between p300 expression, EGF expression, and MVD score No significant correlation was noted between p300 expression, EGF expression, and M D score (Table 3) .
Discussion
ur findings revealed association of di use plasma cell infiltration pattern with increased EGF expression and higher M D scores in patients with PCM. Also, higher percentage of plasma cell infiltration and higher C P levels were associated with increased EGF expression and higher M D scores, respectively. p300 expression was not associated with any of the prognostic factors related to plasma cell infiltration, while none of the angiogenesis-related immunohistochemical parameters was associated with cytological grade or survival. PCM is the first haematological malignancy in which a significant correlation of angiogenesis with prognosis and survival has been identified 16 . Bone marrow M D was shown to be significantly increased in PCM compared to monoclonal gammopathy of undetermined significance (MG S) and also in active versus non-active myeloma 1,17 as well as in stage versus stage myeloma 3 . The type of infiltration pattern is considered to re ect the stage of disease with identification of interstitial and nodular patterns when hematopoiesis is still preserved, unlike occurence of di use in itration with disease progression that results in the supression of hematopoiesis 18 . igh percentage of plasma cells infiltration in bone marrow has been suggested to be a reliable predictor of relapse in PCM patients 19 , while advanced grade plasma cell infiltration pattern, re ecting a high tumor burden, has been associated with high plasma cell count and poor prognosis 20 . EGF activity was shown to be associated with tumor grade and prognosis in PCM, while in vivo inhibition of EGF-induced angiogenesis by antibodies against EGF was reported to result in suppression of tumor growth 8,21 . Also, high tumor burden and di use pattern of infiltration were reported to be associated with higher M D along with a highly significant correlation between M D and histologic grade of tumor, extent of bone marrow infiltration, proliferative activity, and treatment response in patients with PCM 22-24 . ence, association of di use plasma cell infiltration pattern both with increased EGF expression and higher M D score and association of the high percentage of plasma infiltration with increased EGF expression in our cohort seem to indicate the role of angiogenesis in promoting disease progression in PCM and supporting the association of increased angiogenesis with advanced PCM 21 . A high clinical stage/cytological grade in PCM has been associated with higher rate of proliferation, higher intratumoral vascularity, and increased EFG in the neoplastic cells as well as increased M D 2,8 . owever, unlike other plasma cell related prognostic factors including type of bone marrow infiltration and uantity of neoplastic cells, the morphology of the cells was not associated with any of the angiogenesis-related immunohistochemical parameters in our cohort. This seems to be associated with inability to perform appropriate analysis due to observation of high cytological grade only in 2 patients in the overall cohort. Association of higher M D scores with higher C P levels in our cohort seems notable given the consideration of both M D and serum C P levels as the best variables that predict event-free and overall survival among patients with PCM 22 . This also emphasi es the likelihood of C P release in response to angiogenic cytokines, given the positive feedback between EGF and angiogenic cytokines such as -6 to promote angiogenesis in proliferating myeloma cells 8 . Providing data on p300 expression for the first time in the literature, our findings revealed high ( 30 ) amount of p300 expression in more than half of the patients with PCM, whereas there was no association of p300 expression with clinical or prognostic parameters. ence, the potential prognostic role of increased p300 expression in patients with PCM seems to be justified in larger scale studies. ur findings also revealed no correlation between EGF expression, p300 expression, and M D. Similarly to our findings, no correlation between the level of bone marrow M D and plasma levels of EGF was shown in another study 25 . Besides, high M D scores were demonstrated in patients both with high and low EGF expression, indicating the potential role of other angio-regulatory factors in the neo-vascular growth process 8 . Nonetheless, there is inconsistency regarding the correlation of bone marrow angio- genesis and regulatory factors, and a significant correlation between higher EGF expression and an increase in the M D of tumor tissues was also indicated in malignant plasma cell neoplasms 25 . The extent of bone marrow angiogenesis has been reported as a strong indicator of biological potency of malignant clone and a predictor of survival in newly-diagnosed patients with PCM 22-23 . ncreased bone marrow M D was shown to be a significant poor-prognosis factor for survival in patients with newlydiagnosed PCM 6,24 . owever, despite a statistically significant relationship between EGF expression and the S, expression of EGF was not considered to be an independent prognostic factor in a past study among PCM patients 8 . Also no significant di erence was reported between EGF-positive and EGF-negative patients with PCM in terms of overall survival in another study 24 . Bone marrow M D was not found to be significantly correlated with S both at diagnosis and prior to transplant 3 and no correlation was noted between baseline bone marrow M D and PFS and S in PCM patients 25 . ack of any association between increased angiogenesis and poorer survival was also reported in another study among patients with advanced PCM 8 . Patients with well di erentiated plasma cells and low tumor burden with 50 of bone marrow tumor infiltrates were estimated to have favorable prognosis 18 . owever, despite their association with type of bone marrow infiltration and uantity of neoplastic cells, EGF or M D had no association with morphology of the plasma cells and had no impact on survival in our cohort. The lack of a statistically significant association of overall survival with EGF expression and M D scores in our cohort might be attributed to the potential contribution of angiogenic factors other than EGF, the small number of cases in study groups as well as in high-grade cytology group along with the in uence of di erent treatment methods and co-morbid disorders.
Conclusions n conclusion, our findings revealed significant association of bone marrow infiltration pattern and uantity of neoplastic cells but not the morphology of the cells with the angiogenesis-related immunohistochemical parameters. ncreased EGF expression was associated with di use type of bone marrow infiltration pattern and high percentage of plasma cell infiltration, while higher M D score was associated with di use type infiltration pattern and increased C P levels. To the best of our knowledge, this is the first study to date investigating the potential prognostic role of p300 expression in patients with PCM. No association of p300 was shown with histomorphologic prognostic parameters and the angiogenesis-related immunohistochemical parameters and overall survival. Nevertheless, the present study provides the first evaluation and evidence of p300 expression in PCM. Eventually, the interaction between angiogenesis and myeloma cells as well as the prognostic role of increased bone marrow angiogenesis in PCM need further elucidation with larger study groups and longer follow-up.
